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Abstract
Background: Previous work, by us and others, has shown that mammalian galectins-1 have a
growth-inhibitory activity for mammalian cells which is apparently independent of their β -
galactoside binding site.
Results: We have made recombinant human galectin-1 as a bacterial fusion protein with an N-
terminal hexahistidine tag. This protein displays both haemagglutination and growth-inhibitory
activities, even in the presence of the hexahistidine tag. Site-directed mutagenesis of this protein
has confirmed the independent nature of the protein sites responsible for the two biological
activities. Mutant proteins were created, which displayed each activity in the absence of the other.
Conclusions: Human galectin-1 possesses a growth-inhibitory site, which is not part of the β -
galactoside binding site. A surface loop, comprising amino acid residues 25–30, and joining two
internal β -strands, forms part of the growth-inhibitory site. This region is relatively close to the N-
terminus of the protein, and N-terminal substitutions or extensions also affect growth-inhibitory
activity. Further experiments will be necessary to fully define this site.
Background
It is now widely accepted that several galectins, and galec-
tin-1 in particular, have biological functions over and
above their obvious role in the binding or cross-linking of
β -galactoside-containing glycans [1–3]. The concept of a
galactose-binding protein as a negative growth regulator
was first seriously proposed when a protein from mouse
fibroblast cultures, the murine homologue of galectin-1,
was shown to have both properties [4]. These workers
went on to demonstrate that growth-inhibitory activity of
this mGBP was present even when it bound a glycan at its
galactose-binding site [5], suggesting that the two proper-
ties were independent functions of galectin-1. In fact, evi-
dence for a growth-inhibitory phase could be seen in
several earlier reports of the mitogenic activity of galectins
from other species [6–8]. There was some evidence for a
similar activity associated with human galectin-1, and it
was suggested that proteolysis of secreted galectin-1 could
account in part for the action of a growth-related cell-sur-
face proteinase [9].
In an attempt to test this hypothesis, recombinant human
galectin-1 was prepared as a bacterial fusion protein with
glutathione-S-transferase [10]. Both the fusion protein,
and the galectin-1 derived from it by proteolysis and re-
purification, functioned as multivalent lectins, and dis-
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played mitogenic activity, which was inhibited by lactose.
Growth-inhibitory activity was not a property of the intact
GST-galectin fusion protein, but only of the cleaved and
purified galectin-1, and lactose did not inhibit this activi-
ty. It seemed likely that the GST domain of the fusion pro-
tein may sterically restrict access to a growth-inhibitory
site on the galectin domain, but it clearly did not have a
similar steric effect upon the galactose-binding site. These
observations strengthened the case for independent galac-
tose-binding and growth-inhibitory sites on the galectin-1
molecule.
Specific mutagenesis of the recombinant galectin mole-
cule is an obvious way of confirming this conclusion.
Consideration of both tertiary structure and mutagenesis
studies suggests that histidine-45, asparagine-47, ar-
ginine-49, tryptophan-69, glutamate-72 and arginine-74
are all involved in, or influence, sugar binding [11–14].
(In numbering galectin-1 amino acid residues, we have
found it more convenient to number from the N-terminal
methionine, rather than to use the convention of Abbott
and Feizi [15], who numbered from alanine-2, which is
the N-terminus of the mature, natural protein). It should
thus be straightforward to make a substitution mutant of
galectin-1, in which galactose-binding activity is greatly
reduced, or totally ablated. The assay of growth-inhibitory
activity in such a mutant should indicate the existence, or
otherwise, of a separate growth-inhibitory site. The earlier
mutagenesis studies also suggest, however, that the yield
and/or solubility of bacterial mutant galectins may often
be low [11,14]. Our own experience was of poor solubility
and yield for mutated or truncated GST-galectin fusion
proteins (A. Cameron, K.Y. Chung and KS, unpublished
observations). In attempting this study, we therefore
thought it worthwhile to adopt another expression vector.
The ProEX system produces fusion proteins with a short
N-terminal extension, containing a hexahistidine se-
quence for nickel ion chelation chromatography [16].
This was chosen to produce recombinant proteins that
were not dependent on β -galactoside binding for their pu-
rification, and were at the same time smaller, to minimise
problems due to poor solubility and to steric interference
between domains.
It may also be possible to identify a growth-inhibitory site
directly by site-specific mutagenesis. The steric interfer-
ence with growth-inhibitory activity, exerted by the GST
domain attached to the N-terminus of galectin-1 in the fu-
sion protein, does offer some insight into the possible lo-
cation of such a site. Consideration of the three-
dimensional structure of galectin-1 [12,13], in conjunc-
tion with that observation, suggested additional sites for
mutagenesis. The structure bears a strong resemblance to
that of galectin-2 [17]. Each monomer has a β -sandwich
structure, comprising two antiparallel β -sheets of six (S1–
S6) and five (F1–F5) strands, respectively. The β -strands
are joined by turns or relatively short loops; almost 70%
of the amino acids are in β -strands. The galactose-binding
site is comprised of residues in the S4, S5, S6 and F3
strands. The N- and C-termini of the monomer are located
close together, on the opposite side of the structure from
the galactose-binding site. The surface that incorporates
both termini is the contact region in the self-association of
two monomers. Whilst it seems unlikely that the growth-
inhibitory site could be directly on this "dimerisation in-
terface", it may be close to it, as deduced from the steric ef-
fects of N-terminal extension. We identified the surface
loops of the structure, located close to this interface, and
distant from the galactose-binding site, and chose conven-
ient amino acids within them for mutagenesis.
Using this rationale, we have created mutant proteins,
which displayed either galactoside-binding or growth-in-
hibitory activites in the virtual absence of the other. A sur-
face loop, comprising amino acid residues 25–30, and
joining two internal β -strands, forms part of the growth-
inhibitory site. This region is relatively close to the N-ter-
minus of the protein, and N-terminal substitutions or ex-
tensions also affect growth-inhibitory activity.
Results and discussion
Figure 1 summarises SDS-PAGE analysis of several of the
galectin-1 preparations. The hexahis-galectin-1 fusion
protein corresponds to a protein band at about 16 kDa,
and most preparations contain traces of a dimer at about
32 kDa, as was previously observed with GST-galectin-1
[10]. Despite the altered expression system, many mutant
fusion proteins were still produced in low yields. In most
cases where the yield of a mutant was low, there was a
strong protein band at 16 kDa in the bacterial pellet, prob-
ably indicating protein precipitation following expression
(not shown). As noted below, several of the mutants tend-
ed to precipitate slowly at the higher concentrations used
for testing cell growth inhibition, and we also noted that
some of these proteins precipitated even from much more
dilute solutions after prolonged storage at -20°C. Table 1
summarises our findings with each of the mutants of ga-
lectin-1. Two of the mutant proteins (R49G and D47N)
were produced in such low yields that complete experi-
mental investigation was not feasible, but the partial find-
ings were of some interest. In addition to these positive
cases, we also created cDNAs corresponding to the mu-
tants V6D and A28D, but in neither case could we detect
expressed protein in E. coli DH5α .
One hope was that, with a relatively small fusion peptide
tag, the recombinant hexahis-galectin-1 (wild-type)
would display full biological activities without the need
for proteolytic cleavage and protein re-purification. This
was indeed the case. The endpoint of the haemagglutina-BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/3
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Figure 1
Electrophoresis of Galectin-1 Preparations SDS-PAGE analysis of 15% gels of recombinant human galectin-1 prepara-
tions A a) marker proteins b) bacterial lysate containing M1R mutant galectin-1 c) M1R galectin-1, purified by affinity chroma-
tography d) normal galectin-1, purified by affinity chromatography B e) marker proteins f) purified D27N galectin-1 g) purified
K29M galectin-1 h) purified K29T galectin-1
Table 1: Summary of Galectin-1 Mutations 
Mutation Yield (mg/l culture) Haemagglutination. Endpoint 
(µg/ml)
Growth Inhibition I50 (µg/ml)
None 8.0 1 5
R49G* 0.1 1 nd
N47D* 0.1 100 nd
A28R* 0.3 - >200
D103A 9.2 1 20
P79R 0.6 500 4
C131S 0.5 - 13
K29M 8.0 1 -
K29T 8.2 1 -
D27N 0.8 1 170
M1R 10.4 1 -
M1R (thrombin) n/a 1 24
Yields and Biological Activities of Recombinant Galectin-1 Derivatives For each mutation in galectin-1, the yield of protein per litre of bacterial cul-
ture, the endpoint of the haemagglutination titration (in µg/ml) and the concentration giving 50% inhibition of fibroblast growth (I50, in µg/ml) are 
listed. The three entries marked * are for low-yield mutations, for which full analysis was not feasible. The final row contains data for the M1R 
mutant following thrombin cleavage and repurification.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/3
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tion titration was 1 µg/ml for the hexahis-galectin-1, com-
pared to 1.3 µg/ml for the GST-galectin 1 fusion protein.
It should also be noted that the growth-inhibitory activity
seen here (I50 = 5 µg/ml) was about 12–15 times greater
than with the recombinant galectin-1 cleaved from a GST-
galectin 1 fusion protein by thrombin [10], and roughly
comparable with that of natural human galectin-1 [9]. It
is still, however, about tenfold less active than recom-
binant mouse or human galectin expressed in COS-1 cells
[4,22]. The different growth-inhibitory activities of our
two recombinant galectins-1 may indicate that the chem-
ical nature of the N-terminal extensions may have a great-
er effect on this activity than their size, though a very large
extension, such as the entire GST molecule, was clearly in-
hibitory. Although the linker peptide of hexahis-galectin-
1 contains a renin-sensitive site for proteolysis, renin ac-
tion was not tested experimentally, as it would still leave
an N-terminal tripeptide extension.
Arginine-49 is located in the S4 β -strand, in the scheme of
Lobsanov et al.[18]. To our knowledge, it has not been
modified in galectin-1 before now, but it has been shown
to be located at the galactose-binding site, interacting with
the 4-hydroxyl of the galactose residue, in the three-di-
mensional structures proposed by Bourne et al.[12] and
Liao et al.[13]. We thus expected that the R49G mutant ga-
lectin-1 would show reduced, or at least altered lectin ac-
tivity, but in fact it was not significantly different from
that of the control recombinant galectin-1. Because the
yield of soluble protein was low, no further work was
done with this mutant. A D47N mutation, also in the S4
β -strand, has been previously reported as lectin-negative
[14]. We were able to confirm this finding, but, again, the
yield of soluble protein was too low to carry out further
experiments.
In the cases of two mutant proteins with reduced haemag-
glutination activity, additional experiments were done, to
distinguish between a failure to bind to erythrocyte sur-
Figure 2
Gel Filtration of Recombinant Galectin-1 and Variants. Galectin-1 preparations purified by metal chelation chromatog-
raphy were subjected to gel filtration on a Sephadex G-50 gel filtration column (60 ×  1 cm; equilibrated in 30 mM Tris-HCl
buffer pH 7.5). Fractions of 2 ml were collected, and absorbances at 280 nm measured. Њ Normal galectin-1 ▪ N46 D mutant
 P79R mutant   Bacterial lysozyme.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/3
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face β -galactoside binding sites, and a reduction in eryth-
rocyte cross-linking, either of which would result in
reduced haemagglutination. Pretreatment with saturating
concentrations of the mutant galectin-1 was followed by a
haemagglutination titration with wild-type galectin-1. For
both the P79R and the C131S mutants, this procedure re-
sulted in agglutination at approximately the same end-
point (1 µg/ml) as with wild-type galectin-1 in a control
experiment. If the mutant galectin-1 was binding to the
erythrocyte surface, but failing to cross-link erythrocytes,
we would have expected to see reduced haemagglutina-
tion with the wild-type galectin, as the mutant would
block binding sites. Thus, in each case, the mutations dis-
rupt the β -galactoside binding site, rather than the dimer-
isation of the galectin-1. This finding was confirmed by
failure of the mutant protein in lectin-affinity chromatog-
raphy (not shown). The dimeric nature of several of the
mutant galectins-1, including P79R, is also shown by gel
filtration (Figure 2). Lysozyme (14.5kDa) was used as a
standard, which would co-elute with the galectin-1 mon-
omer, but it is clear that all of the galectin preparations are
substantially bigger under non-denaturing conditions.
The P79R mutation occurs in a conserved, surface loop,
between the S6 and F3 β -strands. It is relatively distant
from the galactose-binding site, but is closer to the dimer-
isation interface of galectin-1 [12,13]. It was thus some-
what surprising that this mutant protein had a greatly
reduced haemagglutinin activity, over two orders of mag-
nitude below the control. This reduction was due to a loss
of affinity for glycans, rather than to loss of cross-linking
ability. Equally surprising was the observation that P79R
retained full antiproliferative activity. Even if the substitu-
tion affects glycan binding as a consequence of a generally
disruptive effect on tertiary structure, the retention of
growth-inhibitory activity is significant. This is a clear con-
firmation that the galactose-binding and growth-inhibito-
ry sites of galectin-1 are largely or wholly independent. It
may be noteworthy that the elimination of the galactose-
binding activity does not seem to result in more produc-
tive binding at the growth-inhibitory site.
The C131S mutation is also located close to the dimerisa-
tion interface, but in a surface β -strand (F1), rather than a
loop. This galectin-1 variant was produced in low yield,
and was totally devoid of haemagglutinin activity, but re-
tained most of the growth-inhibitory potential of the
wild-type. The loss of haemagglutinin activity is apparent-
ly caused by disruption of the β -galactoside-binding site.
An earlier analysis of a C131S substitution confirmed the
low yield of protein, but reported a relatively normal lac-
tose binding value [14]. Substitutions in the extreme N-
terminal region have been reported to disrupt hamster ga-
lectin-1 dimerisation, but concomitant substitutions in
the C-terminus (F127, I129 and V132) led to a loss of lac-
tose-binding affinity [23].
Cysteine-131 can potentially form a disulphide bond with
C2, but failure to make this, and other disulphide bonds
(C17 – C89 and C43 – C61), favours lectin activity [11].
A human galectin-1 variant with all six cysteines replaced
by serines retains haemagglutinating activity [24]. It has
been shown that the oxidative loss of lectin activity corre-
lates with the formation of disulphide bonds [25], and
two more recent reports suggest that some biological ac-
tivities are associated only with this structural form
[24,26]. In the present case, the ability to demonstrate lec-
tin and growth-inhibitory activity with identical galectin-
1 samples argues against the proposal that the growth-in-
hibitory activity is a property only of the oxidized, disul-
phide-bonded form.
The D103A mutation is located in a surface loop, connect-
ing adjacent antiparallel β -strands (F4–F5), but is distant
from both the dimerisation interface and the galactose-
binding site. This substitution did not appear to affect the
lectin function of galectin-1 (Table 1), though growth-in-
hibitory activity was somewhat reduced, and the titration
of this activity was obscured by precipitation at higher
concentrations. This latter finding was somewhat surpris-
ing, in view of the very high yield of this protein (8 mg/l)
in the bacterial expression system.
Following our failure to detect expression of an A28D mu-
tant (in another surface loop, F2–S3), we were able to ex-
press an A28R mutant, though the A28R protein was in
low yield, and impure following Ni-NDA affinity chroma-
tography, and we were unable to further purify it by
Sephadex gel filtration or galactosyl-agarose affinity chro-
matography (not shown). An unknown protein of about
25 kDa was a persistent contaminant. The data reported in
Table 1 was obtained with a protein sample containing
50–60% of the galectin-1 component, as estimated from
the SDS-PAGE result. Again, the mutation affected galac-
tose binding, but, in this case, growth-inhibitory activity
was also greatly reduced. Despite the reservations im-
posed by the low yield and impurity of the sample, this
observation offered a clue to the possible localization of
the growth-inhibitory site, and we decided to make fur-
ther mutational substitutions in this region of galectin-1.
The K29M mutation, also in the F2–S3 loop, resulted in a
galectin that retained its galactose-binding activity. Test-
ing of growth-inhibitory activity was initially obscured by
the precipitation of this protein at high concentrations
(above 100 µg/ml), but it became clear that it had totally
lost its ability to inhibit fibroblast growth. Whilst this rad-
ical substitution, of a moderately hydrophobic amino
acid for a charged residue, clearly had an effect upon theBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/3
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solubility of the protein, (though, again, not on protein
expression) the complete retention of lectin activity ar-
gued for the maintenance of overall three-dimensional
structure. The K29T mutant, with a less radical substitu-
tion, was also a normal lectin, but equally devoid of
growth-inhibitory activity (see Table 1). As a further check
upon the importance of this part of the galectin-1 mole-
cule to its growth-inhibitory activity, a D27N mutant was
made and tested, and demonstrated full lectin activity, but
significantly reduced growth-inhibitory activity (Table 1).
If the D27 – K29 region of galectin-1 is part of a growth-
inhibitory site, then the effect of N-terminal modifica-
tions on growth-inhibitory activity may be explicable, as
the "natural" amino terminus is within 8–10 Angstroms
of these amino acids [12]. It seems possible that the reduc-
tion of this activity, seen in both of our recombinant ga-
lectin types, hexahis- and GST-derived, may be due to
modification of the N-terminus. As already discussed, it
cannot simply be a steric restriction by the extended N-ter-
mini, as this would have a more marked effect on hexahis-
galectin-1, whereas the reverse is true. To further investi-
gate this region, we designed a forward PCR primer in-
tended to substitute methionine-1 with an arginine
(M1R). The M1R fusion protein was expressed in high
yield, and was fully functional as a haemagglutinin, but
was devoid of growth-inhibitory activity (Table 1). Rather
than allowing it to substitute for the terminal amino
group, the positioning of the positively-charged arginyl
side-chain acts to inhibit the action of the growth-inhibi-
tory site, which helps confirm that the N-terminal region
of the normal protein is close to, or part of this site.
It also seemed possible that thrombin might remove the
N-terminal 14-residue peptide (hexahis-linker-arginine)
from the M1R recombinant protein, and thus re-create the
natural, methionine N-terminus. Thrombin treatment
and repurification of the protein resulted in a fraction that
did not bind to the Ni-NDA-agarose affinity column, so
had lost the N-terminal hexahis region. It retained hae-
magglutinin activity, and had also recovered growth-in-
hibitory activity, though was not as effective as the wild-
type galectin-1. It is possible that this reduction in growth-
inhibitory activity (I50 = 24 cf 5 for wild-type galectin-1)
reflects the effect of other thrombin cleavages within the
molecule, as was seen previously with the GST-derived ga-
lectin-1 [10]. In this case, N-terminal amino acid sequenc-
ing, following removal of the GST with thrombin revealed
a minor component corresponding to the sequence begin-
ning at F50. We deduced that this could be due to a
thrombin cleavage at R49-F50. This protein was indistin-
guishable from intact recombinant galectin-1 in SDS-
PAGE. In the present case, we have not examined this ex-
perimentally.
Figure 3, derived from a structural model [12], shows the
part of the protein (shaded region c) that has been dem-
onstrated to have a role in the growth-inhibitory activity.
The β -galactoside-binding site (region a), and the dimeri-
sation interface (region b) are also indicated. The ele-
ments of the growth-inhibitory site that have so far been
identified would all be contained within a truncated ga-
lectin-1, containing the first 35 residues (the S1, F2 and S3
β -strands, and connecting loops), in addition to the fu-
sion tag. Although we were able to amplify this part of the
galectin-1 cDNA, and clone it into the ProEx vector, we
Figure 3
Location of Active Sites within the Galectin-1 Struc-
ture This figure is adapted from one designed to show the
three-dimensional structure of galectin-1 (Bourne et al.,
1994). The three shaded boxes indicate regions involved in
glycan binding (a), dimerisation (b), and cellular growth inhibi-
tion (c).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/3
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were unable to detect any expression in E. coli (not
shown).
Fusion proteins with an N-terminal tag have given valua-
ble clues to the nature of the growth-inhibitory site, but,
for further elucidation of the involvement of the N-termi-
nus, it would be better in the future to use C-terminally-
tagged proteins, or to express galectin-1 without any tag,
and to use glycan-agarose affinity chromatography for pu-
rification of the recombinant proteins. The extreme C-ter-
minus is also part of the dimerisation interface, but points
in the opposite direction to the N-terminus (see Figure 3),
so C-terminal extensions may not affect the growth-inhib-
itory site, though, as already noted, C-terminal substitu-
tions may inhibit β -galactoside binding [22].
The D27 – K29 region forms part of a DAKSF sequence
(residues 27–31) that is totally conserved in the mamma-
lian galectins-1 [27], but is totally different from the cor-
responding residues in other galectins [28], for which
growth-inhibitory properties have not been reported.
However, there is no strong argument here for the evolu-
tionary conservation of a functional part of the galectin-1
structure. Most of the sequences of the mammalian ga-
lectins-1 are strongly conserved throughout, whereas,
when we consider the whole galectin family, the inter-
strand loops, and even the β -strands not involved in galac-
tose binding, are not strongly conserved.
Conclusions
In summary, we have shown that we can ablate the β -ga-
lactoside binding activity of human galectin-1 by muta-
tion, with no effect on the cellular growth-inhibitory
activity, confirming that these are two independent func-
tions of the protein. By further mutational studies, we
have at least partially defined the amino acids that make
up the growth-inhibitory site in galectin-1. A surface loop,
comprising amino acid residues 25–30, and joining two
internal β -strands, contains amino acids which contribute
to the growth-inhibitory site. This region is relatively close
to the N-terminus of the protein, and N-terminal substitu-
tions or extensions also affect growth-inhibitory activity.
Further mutational studies may be necessary to fully de-
fine the growth-inhibitory site.
The ProEX expression system offers some advantages in
the production of bacterial recombinant galectin-1. Our
original interest in galectin-1 was as a putative substrate
for a growth-regulatory, cell-surface proteinase [9]. Inhibi-
tion of the proteinase led to an accumulation of endog-
enous galectin-1 in the culture medium. The inhibitory
action of this galectin-1 could, at least in part, account for
the growth-inhibitory effect observed when the proteinase
was inhibited. The fact that the recombinant hexahis-ga-
lectin-1 has a similar growth-inhibitory activity to the nat-
ural protein means that it can be used more realistically in
future experiments in this area.
Some of these mutants may enable us to assess the signif-
icance of each galectin-1 function to tumour growth and
metastasis. We have shown that HEp-2 tumour cells do
not express galectin-1, but respond to exogenous galectin-
1 as a growth inhibitor [10]. Transfection of HEp-2 cells
with each galectin-1 gene variant will permit the study of
effects on growth and metastasis, both in vitro, and then in
vivo. The galectin-1 variant, P79R, which retains growth-
inhibitory activity and reasonable solubility, but has little
lectin activity, may be the starting-point for the creation of
an effective antitumour agent. It would not have the mi-
togenic activity seen with native galectin-1 [10], nor
would it be involved in non-productive binding to galac-
tosides in the extracellular matrix. This galectin-1 variant
could also be used to identify the cellular receptor respon-
sible for the growth-inhibitory effect, since binding to cel-
lular glycans will be minimised.
Materials and methods
Cloning and mutation of the galectin-1 gene
Unless otherwise noted, molecular biology reagents were
purchased from Gibco-BRL and all other reagents were
from Sigma. The plasmid expression vector ProEX was
purchased as part of a kit, which also included the corre-
sponding nickel-containing affinity matrix. We used
standard protocols for techniques such as DNA restriction
and ligation, bacterial transformation, and agarose gel
electrophoresis [18].
Galectin-1 cDNA was re-amplified from human fibroblast
cDNA, using the GRP3 and GRP4 primers, as previously
described [10]. Specific mutations were introduced using
the Overlap Extension PCR technique [19], which uses
complementary forward and reverse oligonucleotide
primers incorporating the intended substitution. Primers
were used as specified in Table 21, in conjunction with the
GRP3 and 4 primers. For mutations close to either end of
the galectin-1 gene, extended and modified versions of
GRP 3 or 4 were used. MasterMix (Qiagen; 25 µl) was used
as a source of buffer, nucleotides and polymerase for the
PCR reaction, together with 20 pmol of each primer and 2
µg template DNA in a final volume of 50 µl, containing 1
mM Mg Cl2. Thirty cycles of PCR were performed, with 30
s at 95°C for denaturation, 90 s at 55°C for annealing, and
60 s at 72°C for polymerase extension. In some cases, the
55°C annealing temperature was inappropriate for partic-
ular overlapping primers, and was modified to suit the
primer composition, usually to 45–47°C. The amplified
product was run on a 1.0% agarose horizontal gel in 40
mM Tris-acetate, pH 8.0, containing 1 mM EDTA buffer,
cut out of the gel and purified using the Rapid Extraction
protocol (Gibco-BRL). The product was restricted withBMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/3
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BamH I and SalI restriction enzymes and ligated using T4
DNA ligase into the ProEX HTb vector restricted with the
same enzymes, then transformed into competent E. coli
DH 5α  cells, as previously described [10]. After plating on
ampicillin-L-broth agar culture plates, to select plasmid-
bearing clones, PCR was used to screen cloned colonies
for transformants, using part of each colony as a source of
the template, with the GRP 3 and 4 primers, and using
agarose electrophoresis to check for the presence of a 450-
bp galectin-1 band [10]. Following PCR amplification and
cloning of normal and of putative mutated galectin-1 cD-
NAs, each was sequenced bidirectionally by a modified
Sanger technique using a 377 Sequencer (ABI) in the Se-
quencing Unit of the School of Biological Sciences, to con-
firm the expected mutated sequence, and to check the
integrity of the rest of the cDNA.
Protein expression and characterisation
Transformant colonies having the insert were innoculated
in 3 ml L-broth/ampicillin medium and grown at 37°C in
a shaking incubator until the absorbance at 600 nm
reached 0.8. At this stage the cultures were induced for 3 h
with 0.6 mM IPTG, and then microfuged for 10 min at
5000 rpm. The cell pellets were boiled in gel loading buff-
er, and applied to a 15% SDS polyacrylamide gel (Biorad),
to test for expression of the fusion protein. For large-scale
expression, 2 litre cultures were grown and induced under
the same conditions. Where protein yields were low, cul-
tures of up to 8 litres were used. The cultures were centri-
fuged in a Sorvall GSA rotor at 5,500 rpm for 10 min to
collect cells and the pellet was resuspended in 10 ml of
ice-cold sodium phosphate-buffered isotonic saline (PBS)
and extensively sonicated at 4°C to lyse the cells. The
lysate was centrifuged (15,000 rpm in Sorvall SS34 rotor
for 20 min) and the supernatant was used for affinity
chromatography.
For affinity purification of the recombinant fusion pro-
teins, a Ni-NDA-agarose column (4 ml) was equilibrated
in 20 mM Tris-HCl buffer, pH 8.5, containing 100 mM
KCl, 5 mM 2-mercaptoethanol, 10% (v/v) glycerol and 20
mM imidazole at room temperature. The culture superna-
Table 2: Oligonucleotide Primers used for Overlap Extension
Mutants Primers
M1R M1R: CTG GGA TCC AGG GCT TGT GGT CTG GTC
GRP4: ACGCGTC GAC TCA GTC AAA GGC CAC ACA
V6D V6D: CTG GGA TCC ATG GCT TGT GGT CTG GAC GCC AGC AAC
GRP4: ACGCGTC GAC TCA GTC AAA GGC CAC ACA
D27N D26N-F: GTG GCT CCT AAC GCT AAG AGC
D26N-R: GCT CTT AGC GTT AGG AGC CAC
A28D A28D-F: GCT CCT GAC GAT AAG AGC TTC
A28D-R: GAA GCT CTT ATC GTC AGG AGC
A28R A28R-F: GCT CCT GAC CGT AAG AGC TTC
A28R-R: GAA GCT CTT ACG GTC AGG TTC
K29M K29M-F: CCT GAC GCT ATG AGC TTC GTG
K29M-R: CAC GAA GCT CAT AGC GTC AGG
K29T K29T-F: CCT GAC GCT ACG AGC TTC GTG
K29T-R: CAC GAA GCT CGT AGC GTC AGG
N47D N47D-F: CTG CAC TTC GAC CCT CGC TTC
N47D-R: GAA GCG AGG GTC GAA GTG CAG
P79R P79R-F: GCT GTC TTT CGC TTC CAG CCT
P79R-R: AGC CTG GAA GCG AAA GAC AGC
D103A D103A-F: AAG CTG CCA GCT GGA TAC GAA
D103-R: TTC GTA TCC AGC TGG CAG CTT
C131S GRP3: CTG GGA TCC ATG GCT TGT GGT CTG GTC
C131S-R: ACGCGTCGACTCA GTC AAA GGC CAC AGA TTT GAT CTT
R49G R49G-F: TTC AAC CCT GGC TTC AAC GCC.
R49G-R: GGC GTT GAA GCC AGG GTT GAA.
Forward primer for galectin-1 geneGRP3: CTG GGATCC ATG GCT TGT GGT CTG GTC (BamH I site is bold and underlined) Reverse primer for 
galectin-1 geneGRP4: ACGC CTCGAC TCA GTC AAA GGC CAC ACA (SaI I site is bold and underlined). Mutagenesis in Galectin-1 In the case 
of internal mutations, the primers listed were used in conjunction with the 5' and 3' primers (GRP3 and GRP4), to make two, overlapping galectin-
1 cDNA fragments, which then were annealed and extended to create galectin-1 cDNA with the intended substitution. In the case of substitutions 
near the ends of the molecule, a modified version of GRP 3 or 4 was used, in conjunction with the other, normal primer, for conventional PCR 
amplification of the cDNA.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/3
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tant was applied at a flow rate of 0.5 ml/min. The column
was then washed with the equilibration buffer until the
A280 of the eluant was stable, and then with 10 ml of 20
mM Tris-HCl buffer, pH 8.5, containing 100 mM KCl, 5
mM 2-mercaptoethanol and 10% (v/v) glycerol, and then
with a further 10 ml of equilibration buffer. The recom-
binant protein was eluted with 20 ml of 20 mM Tris-HCl
buffer, pH 8.5, containing 100 mM KCl, 5 mM 2-mercap-
toethanol, 10% (v/v) glycerol and 100 mM imidazole
[16]. Protein-containing fractions were pooled, desalted
by overnight dialysis against distilled water at 4°C, and
freeze-dried. Protein purity was checked by electrophore-
sis in SDS-PAGE, as already described.
To a recombinant protein with an introduced arginine res-
idue at the N-terminus (mutation M1R), thrombin (1%,
w/w) was added, under the same conditions as were pre-
viously used to cleave GST-galectin-1 fusion proteins [10].
The resulting protein was purified by gel filtration on a
Sephadex G-50 gel filtration column (60 ×  1 cm; equili-
brated in 30 mM Tris-HCl buffer pH 7.5), to remove small
peptides, and was then re-chromatographed on the Ni-
NDA-agarose column, to test for the presence of the N-ter-
minal hexahistidine tag.
Erythrocyte agglutination by recombinant lectins was test-
ed using freshly-trypsinised rabbit erythrocytes [20]. Ag-
glutination experiments were carried out with serial
threefold dilutions of the purified fusion protein in ce-
ramic tiles. Each well contained 100 µl of 1% bovine se-
rum albumin in 0.15 M NaCl, 100 µl of 0.15 M NaCl and
100 µl of erythrocyte suspension, and 100 µl protein solu-
tion (1 mg.ml-1 in phosphate-buffered saline) was used to
start the serial dilution. Visual identification of the end-
point of the titration of agglutination was confirmed by
microscopic detection of agglutinated erythrocytes.
Erythrocyte agglutination by wild-type hexahis-galectin-1
(unmodified, apart from the fusion tag) was maximal at
concentrations of 100–300 µg.ml-1, and declined at high-
er concentrations. Where agglutination was not observed
with a mutant galectin-1, trypsinised rabbit erythrocytes
were incubated with the protein at 250 µg.ml-1 for 30
min, washed several times with saline, and then used for
agglutination testing with wild-type galectin-1, as de-
scribed above, so as to distinguish between a failure of gly-
can binding, or of cross-linking by the mutant protein.
Tissue culture
WI 3 8 or GM 1604A are normal human diploid fibroblast
strains previously used by us in many experiments on
growth-related proteolysis. The conditions for mainte-
nance and culture of cells have been previously described,
as have assays for inhibition of cell proliferation in micro-
well culture plates, using an ELISA spectrophotometer to
measure fixed and stained cells [21]. In cell proliferation
assays, the hexahis-galectin fusion proteins were added to
normal culture media at known concentrations. For each
assay series, the galectin-1 concentration was plotted
semi-logarithmically against percentage of cell growth in-
hibition [10], to determine the concentration causing
50% growth inhibition (I50).
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